New Alzheimer’s studies reveal disease biology, risk for progression, and the potential for a novel blood test

Estimated reading time: 1 minutes

• About The Author

Two new papers by a team of researchers demonstrate that evaluating microRNAs in blood can be used not only to diagnose mild cognitive impairment (MCI) but also, critically, to predict the conversion from MCI to dementia due to Alzheimer’s disease. Moreover, the researchers uncovered microRNA candidate molecular biomarkers that associate with current Amyloid, Tau, and Neurodegeneration (A/T/N) Alzheimer’s biomarkers.

About The Author

See author's posts

Trending

Android malware steals payment card data using previously unseen technique